Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

This study has been completed.
Sponsor:
Collaborators:
SGS Aster S.A.S.
NATURALPHA
Information provided by (Responsible Party):
Genfit
ClinicalTrials.gov Identifier:
NCT01474161
First received: November 15, 2011
Last updated: November 23, 2012
Last verified: November 2012

November 15, 2011
November 23, 2012
November 2011
November 2012   (final data collection date for primary outcome measure)
  • Pharmacokinetics parameters (Study Part I) [ Time Frame: 24h post-dose ] [ Designated as safety issue: No ]
    For each subject at each Treatment Period, blood will be collected at the following time points: pre-dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h post-dose.
  • Safety parameters (Study Parts II, III and IV) [ Time Frame: Part II : 5 days ; Part III : 20 days ; Part IV : 20 days ] [ Designated as safety issue: Yes ]
    Monitoring for the occurrence of AEs. Changes in physical examination, vital signs (blood pressure and pulse rate), ECG, and clinical laboratory tests (biochemistry, hematology, and urinalysis).
Same as current
Complete list of historical versions of study NCT01474161 on ClinicalTrials.gov Archive Site
  • Safety parameters (Study Part I) [ Time Frame: 12 days for male and 5 days for female ] [ Designated as safety issue: Yes ]
    Monitoring for the occurrence of AEs. Changes in physical examination, vital signs (blood pressure and pulse rate), ECG, and clinical laboratory tests (biochemistry, hematology, and urinalysis).
  • Pharmacokinetics parameters (Study Parts II, III and IV) [ Time Frame: Part II : 24h post-dose ; Part III : 15 days ; Part IV : 15 days ] [ Designated as safety issue: No ]

    Study Part II : For each subject of each dose level, blood will be collected at the following time points: pre-dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h post-dose.

    Study Part III and Study Part IV : Assuming a once daily administration, blood will be collected at the following time points:

    • Day 1 pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h post-dose.
    • Days 3, 7, 10, 11, 12 and 13 pre-dose.
    • Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h post-dose.
Same as current
Not Provided
Not Provided
 
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
Comparative Bioavailability Study of a New GFT505 Formulation With the Existing One After 120 mg Single Oral GFT505 Administration and Assessment of the Gender Effect in Young Healthy Male and Female Volunteers Followed by a Single and Multiple Ascending Dose Safety, Tolerability and Pharmacokinetic Study of GFT505 in Overweight or Obese Subjects and in Diabetic Patients

The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation (capsule dosed at 20 mg GFT505) in healthy male subjects and to assess the impact of gender on this relative bioavailability after administration in male and female subjects.

Using the new formulation, a single and a multiple ascending dose study will be performed in overweight or obese male subjects otherwise healthy whose demographic and physiological characteristics are thought to be closer to those of the target population (Type 2 diabetes). Thereafter, a group of male and female patients with Type 2 diabetes will receive multiple dose administration of GFT505.

The study will be divided in 4 successive parts :

  • Study Part I will be a comparative bioavailability between a new GFT505 formulation (capsule dosed at 60 mg GFT505 by capsule) and the old GFT505 formulation (capsule dosed at 20 mg GFT505 by capsule) coupled with an evaluation of the gender effect assessed with the new formulation. In this purpose a group of 12 male subjects will receive successively both formulations on a unique occasion in a randomized manner while a group of 12 female subjects will receive the new formulation on one occasion only. This part of the study will be done in healthy volunteers.
  • Study Part II will be a single ascending dose to be run at a maximum of 3 dose levels. Subjects included in this part of the study will receive only one dose level to limit the exposure to GFT505. Three cohorts of 8 subjects are planned to be included. This part will be run in overweight or obese subjects.
  • Study Part III will start after completion of the first Cohort of Study Part II. Study Part III will be a multiple ascending dose to be run at a maximum of 3 dose levels. Subjects included in this part of the study will receive only one dose level to limit the exposure to GFT505. Three cohorts of 12 subjects are planned to be included. This part will be run in overweight or obese subjects.
  • Study Part IV will follow the same design and same treatment schedule than Study Part III but will be performed in the target population, patients with Type 2 diabetes and only one dose will be tested in study part IV.
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Type 2 Diabetes
  • Diabetes Mellitus, Type 2
  • Metabolic Diseases
  • Cardiovascular Diseases
  • Obese
  • Dyslipidemia
  • Drug: GFT505 120mg - old formulation
    hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
  • Drug: GFT505 120mg - new formulation
    hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
  • Drug: GFT505 180mg - new formulation
    hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
  • Drug: GFT505 240mg - new formulation
    hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
  • Drug: GFT505 300mg - new formulation
    hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
  • Drug: Placebo
    hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
  • Placebo Comparator: Matching placebo
    Intervention: Drug: Placebo
  • Active Comparator: GFT505 20mg - old formulation
    Study Part I : dose level = 120mg
    Intervention: Drug: GFT505 120mg - old formulation
  • Experimental: GFT505 60mg - new formulation
    Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.
    Interventions:
    • Drug: GFT505 120mg - new formulation
    • Drug: GFT505 180mg - new formulation
    • Drug: GFT505 240mg - new formulation
    • Drug: GFT505 300mg - new formulation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
96
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Part I :

  • Male or female healthy volunteers 18 to 45 years of age (inclusive).
  • Subjects with a body mass index (BMI) ≥ 18 and ≤ 28 kg/m2 at screening.
  • For female subjects of childbearing potential, use of double contraception method.
  • Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator.

Part II and III :

  • Male healthy volunteers 18 to 55 years of age (inclusive).
  • Subjects with a BMI >28 and <35 kg/m2 at screening.
  • Normal arterial BP and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator.

Part IV :

  • Male or female Type 2 diabetic patients 18 to 60 years of age.
  • Females participating in the study must be either of non-child bearing potential or using an efficient double contraception.
  • Currently treated with any antidiabetic treatment (a maximum of two anti-diabetic drugs including metformin in all cases) with the exception of insulin or GLP analogs and agonists therapy.
  • Stable diabetes with glycosylated hemoglobin (HbA1c) < or =10% or less.
  • Normal renal function as defined by a creatine clearance >90 mL/min calculated with the Cockcroft-Gault formula.
  • Subjects with a BMI from 18 to 32 kg/m2 at screening.

Exclusion Criteria:

Part I :

  • Who previously received GFT505.
  • With any clinically significant abnormality following review of prestudy laboratory tests (Aspartate and Alanine aminotransferase must be within normal ranges), vital signs, full physical examination and Electrocardiogram.
  • Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 (Human immunodeficiency virus) or anti-HCV (Hepatitis C virus) antibodies.
  • Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol).
  • Who drink more than 8 cups daily of beverage containing caffeine.
  • Who have a positive laboratory test for urine drug screening (opiates, cocaine, amphetamine, cannabis, benzodiazepines).
  • Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study.
  • Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration.

Part II and III : specific additional exclusion criteria

- Who have taken fibrates within 6 weeks prior to the first dose administration.

Part IV : specific additional exclusion criteria

  • With unstable proliferative retinopathy, macular oedema (fundus examination performed in the previous year will be considered relevant on Investigator's judgement).
  • Who have taken fibrates within 6 weeks prior to the first dose administration.
Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01474161
GFT505-111-7, 2011-004723-13
No
Genfit
Genfit
  • SGS Aster S.A.S.
  • NATURALPHA
Study Director: Rémy Hanf, Development Director GENFIT, France
Principal Investigator: Philippe Betting, MD SGS Aster S.A.S., Phase I Clinical Unit, France
Genfit
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP